Summary for doctors
- First line in ovarian cancer after surgery or before interval surgery; 6 cycles [1].
- Weekly paclitaxel gave no benefit in European patients [1] but improved survival in Japan [2].
- BRCA and HRD testing for maintenance treatment (PARP inhibitor or bevacizumab).
Dose and schedule
Carbo/Pac every 3 weeks
Ovarian, fallopian tube and peritoneal cancer; first lineCycle length: Every 21 days
Ovarian, fallopian tube and peritoneal cancer; first line
| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Paclitaxel | 175 mg/m² | IV over 3 hours | Day 1 |
| Carboplatin | AUC 5 to 6 | IV | Day 1 |
The standard arm of ICON8 [1].
Weekly paclitaxel (dose-dense)
Alternative; in older or frail patients the weekly schedule is less toxicCycle length: Every 21 days
Alternative; in older or frail patients the weekly schedule is less toxic
| Drug | Dose | Route | Schedule |
|---|---|---|---|
| Paclitaxel | 80 mg/m² | IV | Days 1, 8 and 15 |
| Carboplatin | AUC 6 | IV | Day 1 |
As in JGOG 3016 [2].
Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.
Premedication and supportive care
- Paclitaxel premedication; antiemetics: carboplatin AUC 4 or more: NK1, 5-HT3 and dexamethasone.
- Carboplatin hypersensitivity becomes more common after several cycles (especially on retreatment).
Monitoring and dose adjustment
- Blood counts and creatinine (Calvert) before each cycle; CA-125.
- Paclitaxel neuropathy.
Main evidence
Show detailsHide
ICON8: weekly paclitaxel did not improve progression-free survival compared with every 3 weeks [1]. JGOG 3016: in Japanese patients, weekly paclitaxel improved progression-free and overall survival [2].
Related cancer types
Treatment regimens (physicians)
Physician tools and lessons
References
2 referencesShow all referencesClose the reference list
Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.
- 1
- 2
This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.
Printed from the website; the full and up-to-date version: https://drdabiri.com/en/regimens/carboplatin-paclitaxel-ovarian/